In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-08-04

AUTHORS

Franck Touret, Magali Gilles, Karine Barral, Antoine Nougairède, Jacques van Helden, Etienne Decroly, Xavier de Lamballerie, Bruno Coutard

ABSTRACT

A novel coronavirus, named SARS-CoV-2, emerged in 2019 in China and rapidly spread worldwide. As no approved therapeutics exists to treat COVID-19, the disease associated to SARS-Cov-2, there is an urgent need to propose molecules that could quickly enter into clinics. Repurposing of approved drugs is a strategy that can bypass the time-consuming stages of drug development. In this study, we screened the PRESTWICK CHEMICAL LIBRARY composed of 1,520 approved drugs in an infected cell-based assay. The robustness of the screen was assessed by the identification of drugs that already demonstrated in vitro antiviral effect against SARS-CoV-2. Thereby, 90 compounds were identified as positive hits from the screen and were grouped according to their chemical composition and their known therapeutic effect. Then EC50 and CC50 were determined for a subset of 15 compounds from a panel of 23 selected drugs covering the different groups. Eleven compounds such as macrolides antibiotics, proton pump inhibitors, antiarrhythmic agents or CNS drugs emerged showing antiviral potency with 2 < EC50 ≤ 20 µM. By providing new information on molecules inhibiting SARS-CoV-2 replication in vitro, this study provides information for the selection of drugs to be further validated in vivo. Disclaimer: This study corresponds to the early stages of antiviral development and the results do not support by themselves the use of the selected drugs to treat SARS-CoV-2 infection. More... »

PAGES

13093

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41598-020-70143-6

DOI

http://dx.doi.org/10.1038/s41598-020-70143-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1129847339

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32753646


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1108", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical Microbiology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiviral Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Betacoronavirus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "COVID-19", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Caco-2 Cells", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chlorocebus aethiops", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Coronavirus Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Approval", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Evaluation, Preclinical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Repositioning", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pandemics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pneumonia, Viral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "SARS-CoV-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Small Molecule Libraries", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vero Cells", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Virus Replication", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Unit\u00e9 Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), 13005, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.483853.1", 
          "name": [
            "Unit\u00e9 Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), 13005, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Touret", 
        "givenName": "Franck", 
        "id": "sg:person.01207573374.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207573374.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Unit\u00e9 Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), 13005, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.483853.1", 
          "name": [
            "Unit\u00e9 Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), 13005, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gilles", 
        "givenName": "Magali", 
        "id": "sg:person.010164303624.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010164303624.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aix-Marseille Univ, INSERM U1068, CNRS UMR7258, Institut Paoli-Calmettes, CRCM, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.463833.9", 
          "name": [
            "Aix-Marseille Univ, INSERM U1068, CNRS UMR7258, Institut Paoli-Calmettes, CRCM, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barral", 
        "givenName": "Karine", 
        "id": "sg:person.0704242265.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704242265.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Unit\u00e9 Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), 13005, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.483853.1", 
          "name": [
            "Unit\u00e9 Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), 13005, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nougair\u00e8de", 
        "givenName": "Antoine", 
        "id": "sg:person.0735102066.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0735102066.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aix-Marseille Univ, INSERM, Lab. Theory and Approaches of Genome Complexity (TAGC), Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.5399.6", 
          "name": [
            "Institut Fran\u00e7ais de Bioinformatique (IFB), UMS 3601-CNRS, Universit\u00e9 Paris-Saclay, Orsay, France", 
            "Aix-Marseille Univ, INSERM, Lab. Theory and Approaches of Genome Complexity (TAGC), Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Helden", 
        "givenName": "Jacques", 
        "id": "sg:person.0626672543.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626672543.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AFMB UMR 7257, Aix-Marseille Universit\u00e9, CNRS, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.5399.6", 
          "name": [
            "AFMB UMR 7257, Aix-Marseille Universit\u00e9, CNRS, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Decroly", 
        "givenName": "Etienne", 
        "id": "sg:person.01332723167.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332723167.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Unit\u00e9 Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), 13005, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.483853.1", 
          "name": [
            "Unit\u00e9 Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), 13005, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Lamballerie", 
        "givenName": "Xavier", 
        "id": "sg:person.01067672041.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067672041.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Unit\u00e9 Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), 13005, Marseille, France", 
          "id": "http://www.grid.ac/institutes/grid.483853.1", 
          "name": [
            "Unit\u00e9 Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M\u00e9diterran\u00e9e Infection), 13005, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Coutard", 
        "givenName": "Bruno", 
        "id": "sg:person.01230212107.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230212107.42"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/s41586-020-2180-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1125975734", 
          "https://doi.org/10.1038/s41586-020-2180-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/d41586-020-00758-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1125734607", 
          "https://doi.org/10.1038/d41586-020-00758-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrmicro.2016.81", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015704176", 
          "https://doi.org/10.1038/nrmicro.2016.81"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/d41573-020-00016-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1125318732", 
          "https://doi.org/10.1038/d41573-020-00016-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/srep31819", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023183379", 
          "https://doi.org/10.1038/srep31819"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/cr.1990.1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028071262", 
          "https://doi.org/10.1038/cr.1990.1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41421-020-0156-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1125712327", 
          "https://doi.org/10.1038/s41421-020-0156-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41429-019-0204-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1117973719", 
          "https://doi.org/10.1038/s41429-019-0204-x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-08-04", 
    "datePublishedReg": "2020-08-04", 
    "description": "A novel coronavirus, named SARS-CoV-2, emerged in 2019 in China and rapidly spread worldwide. As no approved therapeutics exists to treat COVID-19, the disease associated to SARS-Cov-2, there is an urgent need to propose molecules that could quickly enter into clinics. Repurposing of approved drugs is a strategy that can bypass the time-consuming stages of drug development. In this study, we screened the PRESTWICK CHEMICAL LIBRARY composed of 1,520 approved drugs in an infected cell-based assay. The robustness of the screen was assessed by the identification of drugs that already demonstrated in vitro antiviral effect against SARS-CoV-2. Thereby, 90 compounds were identified as positive hits from the screen and were grouped according to their chemical composition and their known therapeutic effect. Then EC50 and CC50 were determined for a subset of 15 compounds from a panel of 23 selected drugs covering the different groups. Eleven compounds such as macrolides antibiotics, proton pump inhibitors, antiarrhythmic agents or CNS drugs emerged showing antiviral potency with 2\u2009<\u2009EC50\u2009\u2264\u200920\u00a0\u00b5M. By providing new information on molecules inhibiting SARS-CoV-2 replication in vitro, this study provides information for the selection of drugs to be further validated in vivo. Disclaimer: This study corresponds to the early stages of antiviral development and the results do not support by themselves the use of the selected drugs to treat SARS-CoV-2 infection.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/s41598-020-70143-6", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.8964466", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1045337", 
        "issn": [
          "2045-2322"
        ], 
        "name": "Scientific Reports", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "10"
      }
    ], 
    "keywords": [
      "SARS-CoV-2", 
      "SARS-CoV-2 replication", 
      "SARS-CoV-2 infection", 
      "proton pump inhibitors", 
      "selection of drugs", 
      "pump inhibitors", 
      "antiarrhythmic agents", 
      "antiviral effect", 
      "Prestwick Chemical Library", 
      "therapeutic effect", 
      "CNS drugs", 
      "antiviral potency", 
      "identification of drugs", 
      "antiviral development", 
      "novel coronavirus", 
      "drugs", 
      "cell-based assays", 
      "COVID-19", 
      "drug development", 
      "EC50", 
      "inhibitors", 
      "chemical libraries", 
      "urgent need", 
      "early stages", 
      "potential inhibitors", 
      "clinic", 
      "infection", 
      "disease", 
      "different groups", 
      "CC50", 
      "study", 
      "antibiotics", 
      "FDA", 
      "coronavirus", 
      "therapeutics", 
      "replication", 
      "vivo", 
      "potency", 
      "assays", 
      "effect", 
      "group", 
      "agents", 
      "screen", 
      "subset", 
      "stage", 
      "new information", 
      "positive hits", 
      "development", 
      "compounds", 
      "panel", 
      "hits", 
      "chemical composition", 
      "need", 
      "use", 
      "molecules", 
      "identification", 
      "information", 
      "strategies", 
      "library", 
      "results", 
      "selection", 
      "China", 
      "composition", 
      "time-consuming stage", 
      "robustness"
    ], 
    "name": "In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication", 
    "pagination": "13093", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1129847339"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41598-020-70143-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32753646"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41598-020-70143-6", 
      "https://app.dimensions.ai/details/publication/pub.1129847339"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-10T10:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_838.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/s41598-020-70143-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41598-020-70143-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41598-020-70143-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41598-020-70143-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41598-020-70143-6'


 

This table displays all metadata directly associated to this object as RDF triples.

290 TRIPLES      22 PREDICATES      117 URIs      101 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41598-020-70143-6 schema:about N0c809a7e361e4ff0849473f4ea7ae9bc
2 N13a44716a3fa49a38143b0f4c4b9ca75
3 N17a886cda9f74cf6a8380660af2f01f8
4 N32ab7673f87644aea2013c69ab2f81c5
5 N3c935e2066d5483faf29e4e7e5f274f2
6 N403f4980caf74cf686af068f2d2db2a2
7 N4613c39db19a4132bb9de2ae3c91d579
8 N4d0d1620a2d04fc19ceacbe54931d928
9 N4e979098e02144538df77262fcb3b6e1
10 N560c26bd7668478d921253cd3bbe4ef5
11 N5df778caf22d435aa825b5fe25a5c5aa
12 N6296264aa19e44ae8c2564027e760708
13 N8e9460e382184df3ba41843115121015
14 Nc0d25bf6f8b1470b9b0af1ff58ca7534
15 Nd3a7c268f3164756ab8c957b78605e4c
16 Nd4254694fcd44097a85fb8852cf0b380
17 Ne18f0a5d71784552a9db2d4d8ed6e53c
18 Nf19dfc625aed4f76978491c5e54fee6a
19 anzsrc-for:11
20 anzsrc-for:1108
21 schema:author Nb3173f64443c4542bf885d0d97782cd8
22 schema:citation sg:pub.10.1038/cr.1990.1
23 sg:pub.10.1038/d41573-020-00016-0
24 sg:pub.10.1038/d41586-020-00758-2
25 sg:pub.10.1038/nrmicro.2016.81
26 sg:pub.10.1038/s41421-020-0156-0
27 sg:pub.10.1038/s41429-019-0204-x
28 sg:pub.10.1038/s41586-020-2180-5
29 sg:pub.10.1038/srep31819
30 schema:datePublished 2020-08-04
31 schema:datePublishedReg 2020-08-04
32 schema:description A novel coronavirus, named SARS-CoV-2, emerged in 2019 in China and rapidly spread worldwide. As no approved therapeutics exists to treat COVID-19, the disease associated to SARS-Cov-2, there is an urgent need to propose molecules that could quickly enter into clinics. Repurposing of approved drugs is a strategy that can bypass the time-consuming stages of drug development. In this study, we screened the PRESTWICK CHEMICAL LIBRARY composed of 1,520 approved drugs in an infected cell-based assay. The robustness of the screen was assessed by the identification of drugs that already demonstrated in vitro antiviral effect against SARS-CoV-2. Thereby, 90 compounds were identified as positive hits from the screen and were grouped according to their chemical composition and their known therapeutic effect. Then EC50 and CC50 were determined for a subset of 15 compounds from a panel of 23 selected drugs covering the different groups. Eleven compounds such as macrolides antibiotics, proton pump inhibitors, antiarrhythmic agents or CNS drugs emerged showing antiviral potency with 2 < EC50 ≤ 20 µM. By providing new information on molecules inhibiting SARS-CoV-2 replication in vitro, this study provides information for the selection of drugs to be further validated in vivo. Disclaimer: This study corresponds to the early stages of antiviral development and the results do not support by themselves the use of the selected drugs to treat SARS-CoV-2 infection.
33 schema:genre article
34 schema:inLanguage en
35 schema:isAccessibleForFree true
36 schema:isPartOf N12ea50425ca3401a8bd8c9e05ea1ded1
37 Ne6c453b12a6f418c89980636ac7156f3
38 sg:journal.1045337
39 schema:keywords CC50
40 CNS drugs
41 COVID-19
42 China
43 EC50
44 FDA
45 Prestwick Chemical Library
46 SARS-CoV-2
47 SARS-CoV-2 infection
48 SARS-CoV-2 replication
49 agents
50 antiarrhythmic agents
51 antibiotics
52 antiviral development
53 antiviral effect
54 antiviral potency
55 assays
56 cell-based assays
57 chemical composition
58 chemical libraries
59 clinic
60 composition
61 compounds
62 coronavirus
63 development
64 different groups
65 disease
66 drug development
67 drugs
68 early stages
69 effect
70 group
71 hits
72 identification
73 identification of drugs
74 infection
75 information
76 inhibitors
77 library
78 molecules
79 need
80 new information
81 novel coronavirus
82 panel
83 positive hits
84 potency
85 potential inhibitors
86 proton pump inhibitors
87 pump inhibitors
88 replication
89 results
90 robustness
91 screen
92 selection
93 selection of drugs
94 stage
95 strategies
96 study
97 subset
98 therapeutic effect
99 therapeutics
100 time-consuming stage
101 urgent need
102 use
103 vivo
104 schema:name In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication
105 schema:pagination 13093
106 schema:productId N80a98d3e6e1847e5aab2223fc98d07f1
107 Na9741c99e0714732a79f4bfd76b70d91
108 Nd3ceba280f5d403c890336c944d7bb0b
109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1129847339
110 https://doi.org/10.1038/s41598-020-70143-6
111 schema:sdDatePublished 2022-05-10T10:27
112 schema:sdLicense https://scigraph.springernature.com/explorer/license/
113 schema:sdPublisher N2178617e4f814d2fb1bf142ecf58edc5
114 schema:url https://doi.org/10.1038/s41598-020-70143-6
115 sgo:license sg:explorer/license/
116 sgo:sdDataset articles
117 rdf:type schema:ScholarlyArticle
118 N0c809a7e361e4ff0849473f4ea7ae9bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Cell Survival
120 rdf:type schema:DefinedTerm
121 N12ea50425ca3401a8bd8c9e05ea1ded1 schema:issueNumber 1
122 rdf:type schema:PublicationIssue
123 N13a44716a3fa49a38143b0f4c4b9ca75 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name SARS-CoV-2
125 rdf:type schema:DefinedTerm
126 N17a886cda9f74cf6a8380660af2f01f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Betacoronavirus
128 rdf:type schema:DefinedTerm
129 N2178617e4f814d2fb1bf142ecf58edc5 schema:name Springer Nature - SN SciGraph project
130 rdf:type schema:Organization
131 N2f6d5a3edd6249639574d0a68aed667d rdf:first sg:person.0626672543.46
132 rdf:rest Nca969474e1084818896e2d89feee7270
133 N32ab7673f87644aea2013c69ab2f81c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Chlorocebus aethiops
135 rdf:type schema:DefinedTerm
136 N37310da4040946d8ab0cbaf6a941058f rdf:first sg:person.0704242265.44
137 rdf:rest Ncf120027df614ca29a7be8b3a58a0915
138 N3c935e2066d5483faf29e4e7e5f274f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Pneumonia, Viral
140 rdf:type schema:DefinedTerm
141 N403f4980caf74cf686af068f2d2db2a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Drug Evaluation, Preclinical
143 rdf:type schema:DefinedTerm
144 N4613c39db19a4132bb9de2ae3c91d579 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Humans
146 rdf:type schema:DefinedTerm
147 N4d0d1620a2d04fc19ceacbe54931d928 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Caco-2 Cells
149 rdf:type schema:DefinedTerm
150 N4e979098e02144538df77262fcb3b6e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Coronavirus Infections
152 rdf:type schema:DefinedTerm
153 N560c26bd7668478d921253cd3bbe4ef5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Vero Cells
155 rdf:type schema:DefinedTerm
156 N5df778caf22d435aa825b5fe25a5c5aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Virus Replication
158 rdf:type schema:DefinedTerm
159 N6296264aa19e44ae8c2564027e760708 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Pandemics
161 rdf:type schema:DefinedTerm
162 N80a98d3e6e1847e5aab2223fc98d07f1 schema:name doi
163 schema:value 10.1038/s41598-020-70143-6
164 rdf:type schema:PropertyValue
165 N8e9460e382184df3ba41843115121015 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Drug Approval
167 rdf:type schema:DefinedTerm
168 Na9741c99e0714732a79f4bfd76b70d91 schema:name dimensions_id
169 schema:value pub.1129847339
170 rdf:type schema:PropertyValue
171 Nacbb62e61f584395b79e7e192a0eb157 rdf:first sg:person.01067672041.84
172 rdf:rest Nc6a6e09333b84be18db537d11c8f187a
173 Nb3173f64443c4542bf885d0d97782cd8 rdf:first sg:person.01207573374.33
174 rdf:rest Neb4d1173aef2497396236b1b101cc83c
175 Nc0d25bf6f8b1470b9b0af1ff58ca7534 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Small Molecule Libraries
177 rdf:type schema:DefinedTerm
178 Nc6a6e09333b84be18db537d11c8f187a rdf:first sg:person.01230212107.42
179 rdf:rest rdf:nil
180 Nca969474e1084818896e2d89feee7270 rdf:first sg:person.01332723167.63
181 rdf:rest Nacbb62e61f584395b79e7e192a0eb157
182 Ncf120027df614ca29a7be8b3a58a0915 rdf:first sg:person.0735102066.96
183 rdf:rest N2f6d5a3edd6249639574d0a68aed667d
184 Nd3a7c268f3164756ab8c957b78605e4c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Antiviral Agents
186 rdf:type schema:DefinedTerm
187 Nd3ceba280f5d403c890336c944d7bb0b schema:name pubmed_id
188 schema:value 32753646
189 rdf:type schema:PropertyValue
190 Nd4254694fcd44097a85fb8852cf0b380 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Drug Repositioning
192 rdf:type schema:DefinedTerm
193 Ne18f0a5d71784552a9db2d4d8ed6e53c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name COVID-19
195 rdf:type schema:DefinedTerm
196 Ne6c453b12a6f418c89980636ac7156f3 schema:volumeNumber 10
197 rdf:type schema:PublicationVolume
198 Neb4d1173aef2497396236b1b101cc83c rdf:first sg:person.010164303624.60
199 rdf:rest N37310da4040946d8ab0cbaf6a941058f
200 Nf19dfc625aed4f76978491c5e54fee6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Animals
202 rdf:type schema:DefinedTerm
203 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
204 schema:name Medical and Health Sciences
205 rdf:type schema:DefinedTerm
206 anzsrc-for:1108 schema:inDefinedTermSet anzsrc-for:
207 schema:name Medical Microbiology
208 rdf:type schema:DefinedTerm
209 sg:grant.8964466 http://pending.schema.org/fundedItem sg:pub.10.1038/s41598-020-70143-6
210 rdf:type schema:MonetaryGrant
211 sg:journal.1045337 schema:issn 2045-2322
212 schema:name Scientific Reports
213 schema:publisher Springer Nature
214 rdf:type schema:Periodical
215 sg:person.010164303624.60 schema:affiliation grid-institutes:grid.483853.1
216 schema:familyName Gilles
217 schema:givenName Magali
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010164303624.60
219 rdf:type schema:Person
220 sg:person.01067672041.84 schema:affiliation grid-institutes:grid.483853.1
221 schema:familyName de Lamballerie
222 schema:givenName Xavier
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067672041.84
224 rdf:type schema:Person
225 sg:person.01207573374.33 schema:affiliation grid-institutes:grid.483853.1
226 schema:familyName Touret
227 schema:givenName Franck
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207573374.33
229 rdf:type schema:Person
230 sg:person.01230212107.42 schema:affiliation grid-institutes:grid.483853.1
231 schema:familyName Coutard
232 schema:givenName Bruno
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230212107.42
234 rdf:type schema:Person
235 sg:person.01332723167.63 schema:affiliation grid-institutes:grid.5399.6
236 schema:familyName Decroly
237 schema:givenName Etienne
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332723167.63
239 rdf:type schema:Person
240 sg:person.0626672543.46 schema:affiliation grid-institutes:grid.5399.6
241 schema:familyName van Helden
242 schema:givenName Jacques
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626672543.46
244 rdf:type schema:Person
245 sg:person.0704242265.44 schema:affiliation grid-institutes:grid.463833.9
246 schema:familyName Barral
247 schema:givenName Karine
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704242265.44
249 rdf:type schema:Person
250 sg:person.0735102066.96 schema:affiliation grid-institutes:grid.483853.1
251 schema:familyName Nougairède
252 schema:givenName Antoine
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0735102066.96
254 rdf:type schema:Person
255 sg:pub.10.1038/cr.1990.1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028071262
256 https://doi.org/10.1038/cr.1990.1
257 rdf:type schema:CreativeWork
258 sg:pub.10.1038/d41573-020-00016-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1125318732
259 https://doi.org/10.1038/d41573-020-00016-0
260 rdf:type schema:CreativeWork
261 sg:pub.10.1038/d41586-020-00758-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1125734607
262 https://doi.org/10.1038/d41586-020-00758-2
263 rdf:type schema:CreativeWork
264 sg:pub.10.1038/nrmicro.2016.81 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015704176
265 https://doi.org/10.1038/nrmicro.2016.81
266 rdf:type schema:CreativeWork
267 sg:pub.10.1038/s41421-020-0156-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1125712327
268 https://doi.org/10.1038/s41421-020-0156-0
269 rdf:type schema:CreativeWork
270 sg:pub.10.1038/s41429-019-0204-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1117973719
271 https://doi.org/10.1038/s41429-019-0204-x
272 rdf:type schema:CreativeWork
273 sg:pub.10.1038/s41586-020-2180-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1125975734
274 https://doi.org/10.1038/s41586-020-2180-5
275 rdf:type schema:CreativeWork
276 sg:pub.10.1038/srep31819 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023183379
277 https://doi.org/10.1038/srep31819
278 rdf:type schema:CreativeWork
279 grid-institutes:grid.463833.9 schema:alternateName Aix-Marseille Univ, INSERM U1068, CNRS UMR7258, Institut Paoli-Calmettes, CRCM, Marseille, France
280 schema:name Aix-Marseille Univ, INSERM U1068, CNRS UMR7258, Institut Paoli-Calmettes, CRCM, Marseille, France
281 rdf:type schema:Organization
282 grid-institutes:grid.483853.1 schema:alternateName Unité Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection), 13005, Marseille, France
283 schema:name Unité Des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection), 13005, Marseille, France
284 rdf:type schema:Organization
285 grid-institutes:grid.5399.6 schema:alternateName AFMB UMR 7257, Aix-Marseille Université, CNRS, Marseille, France
286 Aix-Marseille Univ, INSERM, Lab. Theory and Approaches of Genome Complexity (TAGC), Marseille, France
287 schema:name AFMB UMR 7257, Aix-Marseille Université, CNRS, Marseille, France
288 Aix-Marseille Univ, INSERM, Lab. Theory and Approaches of Genome Complexity (TAGC), Marseille, France
289 Institut Français de Bioinformatique (IFB), UMS 3601-CNRS, Université Paris-Saclay, Orsay, France
290 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...